Investigating Seronegative Phospholipase A2 Receptor Positive Primary Membranous Glomerulonephritis in a Young Adolescent Successfully Managed With Rituximab Phospholipase A2 Receptor in Primary Membranous Glomerulonephritis
Journal of Pediatric Nephrology,
Vol. 11 No. 3 (2023),
16 October 2024
https://doi.org/10.22037/jpn.v11i3.44615
Abstract
Membranous glomerulonephritis (MGN) is the most common cause of nephrotic syndrome
in adults worldwide; however, it accounts for only 1.5% to 9% of cases of pediatric
nephrotic syndrome. Detecting phospholipase A2 receptor (PLA2R) and thrombospondin
domain containing 7A (THSD7A) among primary MGN patients has greatly transformed
the diagnosis, treatment monitoring, and prognosis. These biomarkers are rarely undetected
in the serum; however, renal tissue sent for histopathology is stained positive. Most of the
previous reports of pediatric MGN are from adolescents approaching adulthood. We report
a 9-year-old boy presenting with PLA2R-positive primary MGN who was seronegative and
responded very well to 2 doses of rituximab after a failed steroid course.
- Phospholipase A2 receptor (PLA2R)
- thrombospondin domain containing 7A (THSD7A)
- Rituximab
How to Cite
References
Cattran D, Brenchley P. Membranous nephropathy: Thinking
through the therapeutic options. Nephrol Dial Transplant.
; 32(suppl_1):i22-9. [DOI:10.1093/ndt/gfw404] [PMID]
Menon S, Valentini RP. Membranous nephropathy in children:
Clinical presentation and therapeutic approach. Pediatr
Nephrol. 2010; 25(8):1419-28. [DOI:10.1007/s00467-009-1324-
[PMID]
Larsen CP, Messias NC, Silva FG, Messias E, Walker PD. Determination
of primary versus secondary membranous glomerulopathy
utilizing phospholipase A2 receptor staining in
renal biopsies. Mod Pathol. 2013; 26(5):709-15. [DOI:10.1038/
modpathol.2012.207] [PMID]
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular
Diseases Work Group. KDIGO 2021 clinical practice
guideline for the management of glomerular diseases. Kidney
Int. 2021; 100(4S):S1-276. [PMID]
Huang G, Liu F, Yu L, Wang J, Chen J and Mao J. Pediatric
membranous nephropathy: In the novel antigens era. Front
Immunol. 2022; 13:962502. [DOI:10.3389/fimmu.2022.962502]
[PMID]
Lee BH, Cho HY, Kang HG, Ha IS, Cheong HI, Moon KC,
et al. Idiopathic membranous nephropathy in children. Pediatr
Nephrol. 2006; 21(11):1707-15. [DOI:10.1007/s00467-006-
-8] [PMID]
Wang R, Wang M, Xia Z, Gao C, Shi Z, Fang X, et al. Longterm
renal survival and related risk factors for primary
membranous nephropathy in Chinese children: A retrospective
analysis of 217 cases. J Nephrol. 2021; 34(2):589-96.
[DOI:10.1007/s40620-020-00816-y] [PMID]
Maifata SM, Hod R, Zakaria F, Abd Ghani F. Primary membranous
glomerulonephritis: The role of serum and urine biomarkers
in patient management. Biomedicines. 2019; 7(4):86.
[DOI:10.3390/biomedicines7040086] [PMID]
Kumar V, Varma AK, Nada R, Ghosh R, Suri D, Gupta A,
et al. Primary membranous nephropathy in adolescence: A
prospective study. Nephrology (Carlton). 2017; 22(9):678-83.
[DOI:10.1111/nep.12835] [PMID]
Fresquet M, Jowitt TA, Gummadova J, Collins R, O'Cualain
R, McKenzie EA, et al. Identification of a major epitope
recognized by PLA2R autoantibodies in primary membranous
nephropathy. J Am Soc Nephrol. 2015; 26(2):302-13.
[DOI:10.1681/ASN.2014050502] [PMID]
De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza
FC. A proposal for a serology-based approach to membranous
nephropathy. J Am Soc Nephrol. 2017; 28(2):421-30
[DOI:10.1681/ASN.2016070776] [PMID]
Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau
A, Wakselman L, et al. Rituximab for severe membranous
nephropathy: A 6-month trial with extended followup.
J Am Soc Nephrol. 2017; 28(1):348-58. [DOI:10.1681/
ASN.2016040449] [PMID]
Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette
RA, Aslam N, et al. Rituximab or cyclosporine in the treatment
of membranous nephropathy. N Engl J Med. 2019;
(1):36-46. [PMID]
Barrett C, Willcocks LC, Jones RB, Tarzi RM, Henderson
RB, Cai G, et al. Effect of belimumab on proteinuria and
anti-phospholipase A2 receptor autoantibody in primary
membranous nephropathy. Nephrol Dial Transplant. 2020;
(4):599-606. [DOI:10.1093/ndt/gfz086] [PMID]
- Abstract Viewed: 259 times
- pdf Downloaded: 117 times